Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
O. Sitbon, G. Burgess, T. Parpia, H. Ghofrani (Clamart, France; Sandwich, United Kingdom; Giessen, Germany). Effects of sildenafil on 6-minute walk distance (6MWD) and WHO functional class (FC) in pulmonary arterial hypertension (PAH) patients after 1 year of treatment. Eur Respir J 2005; 26: Suppl. 49, 3129

Member's Comments

No comment yet.

Related content which might interest you: Is 6-minute walk distance (6MWD) associated with long-term outcomes in pulmonary arterial hypertension (PAH)? Results from SERAPHIN Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment Year: 2013 The role of per cent predicted 6-min walk distance in pulmonary arterial hypertension Source: Eur Respir J 2010; 36: 1294-1301 Year: 2010 Change in 6 minute walk distance (6MWD) following a familiarisation test and exercise training in patients with chronic obstructive pulmonary disease (COPD): influence of disability Source: Annual Congress 2008 - Rehabilitation and influencing factors Year: 2008 Role of exercise cardiac index to predict NYHA functional class, 6-minute walk test distance and survival in idiopathic, heritable and anorexigen-associated pulmonary arterial hypertension Source: Annual Congress 2011 - Physiology of human pulmonary hypertension Year: 2011 Exercise testing to predict outcome in idiopathic versus associated pulmonary arterial hypertension Source: Eur Respir J 2012; 40: 1410-1419 Year: 2012 Glucocorticosteroid reversibility testing with oral prednisone (²steroid trial²) for 4 weeks: time-response study using serial spirometry and 6-minute walk distance (6MWD) in patients with moderate to severe stable COPD Source: Eur Respir J 2004; 24: Suppl. 48, 429s Year: 2004 Analysis of oxygen saturation (O2 sat.) During the six minutes walk distance (6MWD) test in chronic obstructive pulmonary disease (COPD) patients Source: Annual Congress 2009 - Gas exchange and exercise in respiratory diseases Year: 2009 Improvement of 6-minutes walking test (6MWT) and pulmonary functional status after an inpatient pulmonary rehabilitation program (PRP) in moderate-severe and severe COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 244s Year: 2004 Degree of exercise limitation in COPD: impact on 6 minute walk (6MW) in response to long-acting β-agonist (LABA) treatment Source: Eur Respir J 2007; 30: Suppl. 51, 76s Year: 2007 Clinical significance of falling oxygen saturation per walking distance (ΔSaO2/6MWD) during six minute walk test (6MWT) in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2015 – IPF: clinical aspects Year: 2015 The six minute walk test (6MWT) can predict O2 flows required to prevent exercise induced O2 desaturation in patients with idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Clinical issues in idiopathic pulmonary fibrosis Year: 2010 Is a double 6-minute walk test (6MWT) required as part of the routine assessment of pulmonary rehabilitation (PR) in COPD patients? Source: International Congress 2014 – Physical activity, exercise and physiotherapy in patients with COPD Year: 2014 The influence of O2 on exercise capacity (6-minute-walking-distance, 6MWD) in COPD Source: Annual Congress 2011 - Measuring physical activity and exercise performance in chronic lung disease: implications for rehabilitation Year: 2011 Tadalafil improves exercise capacity and delays time to clinical worsening in patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2008 - Medical treatment of pulmonary hypertension Year: 2008 Interpretation of treatment changes in 6-minute walk distance in patients with COPD Source: Eur Respir J 2008; 32: 637-643 Year: 2008 6MWD in patients with pulmonary arterial hypertension (PAH) Source: Eur Respir J 2003; 22: Suppl. 45, 464s Year: 2003 The 6-min walk distance: change over time and value as a predictor of survival in severe COPD Source: Eur Respir J 2004; 23: 28-33 Year: 2004 The use test valsalva manoevre (VM) in diagnosis pulmonary hypertension (PH) for early rehabilitation of patients with lung sarcoidosis (LS) Source: Eur Respir J 2006; 28: Suppl. 50, 72s Year: 2006 Effect of continued pirfenidone treatment following a ≥ 15% decline in 6-minute walk distance (6MWD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis from 3 pivotal studies Source: International Congress 2016 – New and old therapies for chronic lung diseases Year: 2016 Heart rate responses during the 6-minute walk test in pulmonary arterial hypertension Source: Eur Respir J 2006; 27: 114-120 Year: 2006